DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

Not Applicable

Completed

Conditions: Mucositis
Graft-versus-host Disease

Interventions: Drug: TAC + MMF
Drug: Tac+MTX

First Posted Date: 2006-08-07

Last Posted Date: 2013-05-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 89

Registration Number: NCT00360685

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

Phase 4

Completed

Conditions: Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia, Lymphocytic
Myeloma
Lymphoma

Interventions: Drug: Busulfan
Drug: Fludarabine

First Posted Date: 2006-08-07

Last Posted Date: 2017-03-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 72

Registration Number: NCT00361140

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

Phase 1

Terminated

Conditions: Malignant Melanoma

Interventions: Drug: Karenitecin
Drug: Valproic Acid

First Posted Date: 2006-07-31

Last Posted Date: 2013-11-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT00358319

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Pemetrexed

First Posted Date: 2006-07-12

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 8

Registration Number: NCT00351039

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: melphalan
Drug: topotecan (TPT)
Procedure: Autologous Stem Cell Rescue

First Posted Date: 2006-05-12

Last Posted Date: 2018-03-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 177

Registration Number: NCT00325416

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

Not Applicable

Completed

Conditions: Malignant Melanoma

Interventions: Biological: IL-12p DNA
Procedure: Intratumoral Electroporation

First Posted Date: 2006-05-09

Last Posted Date: 2017-02-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT00323206

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Dendritic Cell Vaccination During Lymphoid Reconstruction

Phase 1

Completed

Conditions: Intraocular Melanoma
Melanoma (Skin)

Interventions: Biological: Autologous Dendritic Cells (DC)
Drug: Fludarabine
Biological: Autologous Lymphocyte Infusion (ALI)

First Posted Date: 2006-04-12

Last Posted Date: 2014-02-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT00313508

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Phase 2

Completed

Conditions: Multiple Myeloma
Plasma Cell Leukemia

Interventions: Drug: Bortezomib
Drug: Melphalan
Procedure: PBSCT

First Posted Date: 2006-03-27

Last Posted Date: 2017-03-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 30

Registration Number: NCT00307086

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

Phase 1

Completed

Conditions: Neoplasms, Advanced

Interventions: Drug: Valproic acid
Drug: Epirubicin
Drug: 5-fluorouracil
Drug: Cyclophosphamide.

First Posted Date: 2005-10-30

Last Posted Date: 2017-02-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 82

Registration Number: NCT00246103

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: docetaxel (Taxotere®)
Drug: ZD1839

First Posted Date: 2005-10-04

Last Posted Date: 2017-03-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 44

Registration Number: NCT00231465

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy